SCM
SION

Soleus Capital Management’s Sionna Therapeutics SION Stock Holding History

Soleus Capital Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Buy
293,500
+25,000
+9% +$954K 0.48% 44
2025
Q4 		$11M Sell
268,500
-145,000
-35% -$5.5M 0.41% 49
2025
Q3 		$12.2M Buy
413,500
+37,500
+10% +$816K 0.61% 39
2025
Q2 		$6.52M Buy
376,000
+136,000
+57% +$1.78M 0.43% 49
2025
Q1 		$2.51M Buy
+240,000
New +$3.92M 0.18% 61

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Soleus Capital Management's SION Position: Q1 2026 in Review

Soleus Capital Management increased its Sionna Therapeutics (SION) stake by 9.3% in Q1 2026, buying an estimated $954K and bringing the position to 293,500 shares worth $11.8M. The position accounts for 0.48% of the portfolio, ranked #44.

Soleus Capital Management first reported a position in SION in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.2M in Q3 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Soleus Capital Management held 293,500 shares of Sionna Therapeutics worth $11.8M as of Q1 2026.
  • Soleus Capital Management bought 25,000 Sionna Therapeutics shares in Q1 2026, an estimated $954K.
  • Sionna Therapeutics made up 0.48% of Soleus Capital Management's portfolio in Q1 2026, its #44 holding.
  • Soleus Capital Management first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Soleus Capital Management's Sionna Therapeutics position peaked at $12.2M in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.